Hizentra is indicated for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
Hizentra may help your CIDP patients address challenges with IVIg

Clinical challenges in CIDP:
- In some patients, poor venous access can make IV infusion difficult1
- Systemic adverse reactions, such as headache and fever, can occur2

Lifestyle burdens in CIDP:
- IV infusions can be costly and constraining3
- Travel to an infusion clinic can be time-consuming and require missing work3
*Based on equivalent dosing in grams. †Hizentra may be administered in 1 or 2 infusions over 1 or 2 consecutive days.
Hizentra is:
- A 20% immunoglobulin, half the volume of 10% IVIg*
- Infused in smaller doses more frequently than IVIg
- Subcutaneous, so no need to find a vein

Hizentra can be:
- Conveniently self-administered, allowing patients to infuse at an appropriate place and time
- Infused in a median time of ~1 hour per infusion†

Consider Hizentra for patients with CIDP who:

Experience IV-Related systemic adverse reactions

Have venous access issues

Clinical Challenges


Require more frequent IV infusions

Seek flexibiltiy, freedom, and control

Lifestyle Burdens

Learn about support services
Below are areas you may find especially helpful when providing Hizentra to your patients.